Navigation Links
MiMedx Group Raises over $4.9 Million through the Exercise of Callable Warrants
Date:8/6/2012

KENNESAW, Ga., Aug. 6, 2012 /PRNewswire/ -- MiMedx Group, Inc. (OTCBB: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that the Company has raised over $4.9 million through the exercise of Callable Warrants issued in conjunction with the October 2010 Private Placement.

The Company exercised its right to redeem the Warrants effective August 3, 2012.  Holders had the option to exercise the Warrants or have them redeemed by the Company.  Over 98% of the Callable Warrants were exercised. 

Parker H. "Pete" Petit, Chairman and CEO, said, "The exercise of these Warrants is a 'win-win' for the Company and our investors, as it strengthens our balance sheet, and provides a nice return for the holders.  The Company intends to use the proceeds for general operating needs, including additional clinical trials, as well as the addition of some key direct sales force hires.  These hires will also help expedite our strategy to expand our direct sales representatives and move  toward a blended sales force."

Cancellation of Second Contingent Warrants

The Company also announced the cancellation of approximately 3.2 million Second Contingent Warrants.  The Warrants had been issued to holders that invested in the Company's October 2010 Private Placement and the Senior Secured Promissory Notes issued in December 2011.  More details regarding the terms of the private placement and warrants are disclosed in the Company's SEC filings.

About the Company

MiMedx® is an integrated developer, manufacturer and marketer of patent protected regenerative biomaterial products and bioimplants processed from human amniotic membrane.  "Innovations in Regenerative Biomaterials" is the framework behind our mission to give physicians products and tissues to help the body heal itself. Our biomaterial platform technologies include the device technologies HydroFix® and CollaFix™, and our tissue technologies, AmnioFix® and EpiFix®. Our tissue technologies, processed from the human amniotic membrane, utilize our proprietary Purion® Process that was developed by our wholly-owned subsidiary, Surgical Biologics, to produce a safe, effective and minimally manipulated implant for homologous use. Surgical Biologics is the leading supplier of amniotic tissue, having supplied over 90,000 implants to date to distributors and OEMs for application in the Ophthalmic, Orthopedics, Spine, Wound Care and Dental sectors of healthcare.

Safe Harbor Statement

This press release includes statements that look forward in time or that express management's beliefs, expectations or hopes.  Such statements are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  These statements include, but are not limited to the expected return for the holders of the warrants and the proposed use of proceeds from the exercise of the  warrants.  These statements are based on current information and belief, and are not guarantees of future performance.  Among the risks and uncertainties that could cause actual results to differ materially from those indicated by such forward-looking statements include that the holders may not realize the expected return on the warrants, that the Company may not employ the proceeds as anticipated, and the risk factors detailed from time to time in the Company's periodic Securities and Exchange Commission filings, including, without limitation, its 10-K filing for the fiscal year ended December 31, 2011. By making these forward-looking statements, the Company does not undertake to update them in any manner except as may be required by the Company's disclosure obligations in filings it makes with the Securities and Exchange Commission under the federal securities laws.


'/>"/>
SOURCE MiMedx Group, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. MiMedx Group to Present at the Canaccord Genuity Annual Growth Conference
2. MiMedx Group Announces Record Second Quarter Results
3. MiMedx Group, Inc. Announces Release Date for 2012 Second Quarter Results
4. MiMedx Group Announces Record First Quarter Results
5. MiMedx Exceeds Revenue Goal for First Quarter of 2012
6. MiMedx Signs Agreement with Systagenix for Global Distribution of EpiFix®
7. MiMedx Group Announces 2011 Results
8. MiMedx to Present at American Academy of Orthopaedic Surgeons Annual Meeting
9. MiMedx Group, Inc. Receives CE Certification for Its CollaFix™ Surgical Mesh CD
10. MiMedx Group Completes $5,000,000 Private Placement
11. MiMedx Group, Inc. to Present at the 6th Annual Canaccord Genuity Cardiovascular, Aesthetics and Metabolic Disorders Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)...  Sangamo BioSciences, Inc. (NASDAQ: SGMO ), the ... Edward Lanphier , Sangamo,s president and chief executive officer, ... ZFP Therapeutic ® development programs and an overview ... on Thursday, February 11, 2016, at the Leerink Partners ... is being held in New York ...
(Date:2/4/2016)... , Feb. 4, 2016 Beike Biotechnology, the ... medical institutions attended a ceremony in late 2015 to ... cell therapy in 2016. --> ... Translation Platform for Personalized Cell Therapy" was hosted by ... Production Center, both subsidiaries of Beike Biotechnology Co., Ltd. ...
(Date:2/4/2016)... --> --> ... pleased to provide the following update on recent corporate developments. ... last 3 months we have significantly increased our cash position ... As a result, we have positioned ourselves to execute on ... and expect that development to continue on schedule. ...
(Date:2/4/2016)... -- Sinovac Biotech Ltd. ("Sinovac" or the "Company") (NASDAQ: ... in China , today announced that ... on February 4, 2016 a preliminary non-binding proposal letter, ... PKU V-Ming ( Shanghai ) Investment Holdings ... ( Shenzhen ) Fund Management Co., Ltd., ...
Breaking Biology Technology:
(Date:2/3/2016)... 2016 Vigilant Solutions announces today that the ... Missouri solved two recent hit-and-run cases ... from Vigilant Solutions. Brian Wenberg explains, ... victim was walking out of a convenience store and witnessed an elderly male ... vehicle, striking his vehicle and leaving the scene.  In ...
(Date:2/2/2016)... 2, 2016 Checkpoint Inhibitors for Cancer ... Are you interested in the future of ... checkpoint inhibitors. Visiongain,s report gives those predictions to ... national level. Avoid falling behind in data ... and revenues those emerging cancer therapies can achieve. ...
(Date:2/1/2016)... Rising sales of consumer electronics ... intuitive gesture control market size ... consumer electronics coupled with new technological advancements to drive ... through 2020   --> ... advancements to drive global touchfree intuitive gesture control market ...
Breaking Biology News(10 mins):